{"id":757184,"date":"2025-08-15T07:38:01","date_gmt":"2025-08-15T07:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=757184"},"modified":"2025-08-15T07:38:01","modified_gmt":"2025-08-15T07:38:01","slug":"niemannpick-type-c-disease-pipeline-insight-2025-targeted-therapies-and-novel-mechanisms-aim-to-halt-neurodegeneration-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/niemannpick-type-c-disease-pipeline-insight-2025-targeted-therapies-and-novel-mechanisms-aim-to-halt-neurodegeneration-delveinsight_757184.html","title":{"rendered":"Niemann-Pick Type C Disease Pipeline Insight 2025: Targeted Therapies and Novel Mechanisms Aim to Halt Neurodegeneration | DelveInsight"},"content":{"rendered":"
\n
\"Niemann-Pick<\/a><\/div>\n
\n
Niemann-Pick Type C Disease Pipeline<\/div>\n<\/div>\n<\/div>\n
The therapeutic pipeline for Niemann-Pick Type C (NPC) disease is advancing to address the urgent need to slow its progressive neurological decline. Current treatments like miglustat delay symptoms but don\u2019t target underlying cholesterol and lipid trafficking defects, highlighting the need for disease-modifying therapies to improve survival and quality of life.<\/div>\n

DelveInsight’s “Niemann-Pick Type C Disease – Pipeline Insight, 2025<\/a><\/strong>” highlights an emerging portfolio of candidates targeting multiple disease pathways—ranging from small molecules that restore lipid homeostasis to gene therapies designed to correct NPC1\/NPC2 mutations. Cyclodextrin-based agents, histone deacetylase (HDAC) inhibitors, and oxysterol derivatives are in advanced stages of development, aiming to enhance cholesterol clearance and reduce neuroinflammation. Novel approaches such as intrathecal delivery of 2-hydroxypropyl-β-cyclodextrin (HPβCD), ASOs targeting NPC gene expression, and adeno-associated virus (AAV)–mediated gene replacement are showing promise in clinical and preclinical studies.<\/p>\n

The 2025 pipeline reflects a strategic shift from symptomatic management to precision interventions that directly address NPC pathophysiology. Growing regulatory support for rare disease innovation, coupled with international patient registry data, is accelerating trial design and recruitment. With advances in targeted small molecules, RNA-based therapeutics, and gene therapy platforms, the coming years may redefine the standard of care for Niemann-Pick Type C, offering renewed hope to patients and families facing this devastating condition.<\/p>\n

Interested in learning more about the current treatment landscape and the key drivers shaping the Niemann-Pick Type C Disease pipeline? Click here<\/a><\/strong><\/p>\n

 <\/p>\n

Key Takeaways from the Niemann-Pick Type C Disease Pipeline Report<\/strong><\/p>\n

• DelveInsight’s Niemann-Pick Type C Disease pipeline analysis depicts a strong space with 3+ active players<\/strong> working to develop 5+ pipeline drugs<\/strong> for Niemann-Pick Type C Disease treatment.<\/p>\n

• The leading Niemann-Pick Type C Disease companies include Zevra Therapeutics, Azafaros, Cyclo Therapeutics, IntraBio, SOM Biotech, ENDECE,<\/strong> and others are evaluating their lead assets to improve the Niemann-Pick Type C Disease treatment landscape.<\/p>\n

• Key Niemann-Pick Type C Disease pipeline therapies in various stages of development include Arimoclomol, AZ 3102, Trappsol Cyclo, IB1001, SOM-0208, NDC 1308,<\/strong> and others.<\/p>\n

• In April 2025, a peer-reviewed update summarized these 2024 approvals and their implications for clinical practice and ongoing trials in NPC.<\/p>\n

• In September 2024, the FDA also approved arimoclomol (Miplyffa) for NPC, providing another treatment option for this lysosomal storage disorder.<\/p>\n

• In September 2024, the FDA approved levacetylleucine (Aqneursa) as the first disease-modifying therapy for NPC, based on IB1001 data.<\/p>\n

 <\/p>\n

Niemann-Pick Type C Disease Overview<\/strong><\/p>\n

Niemann-Pick Type C (NPC) disease is a rare, inherited neurodegenerative disorder characterized by the body’s inability to properly metabolize cholesterol and other lipids within cells. This leads to the accumulation of toxic substances in various organs, including the brain, liver, and spleen, causing progressive neurological decline, liver dysfunction, and respiratory issues. Symptoms typically appear in infancy or childhood but can manifest at any age, and include difficulties with movement, learning disabilities, seizures, and psychiatric problems.<\/p>\n

NPC is caused by mutations in the NPC1 or NPC2 genes, which play critical roles in lipid transport within cells. Currently, there is no cure for the disease, but treatments focus on managing symptoms and slowing disease progression. Research and clinical trials are ongoing to develop therapies that can improve outcomes for affected individuals, including the use of drugs aimed at reducing lipid accumulation or enhancing cellular function.<\/p>\n

Find out more about Niemann-Pick Type C Disease medication at https:\/\/www.delveinsight.com\/report-store\/niemann-pick-type-c-disease-pipeline-insight<\/a><\/p>\n

 <\/p>\n

Niemann-Pick Type C Disease Treatment Analysis: Drug Profile<\/strong><\/p>\n

Trappsol Cyclo: Cyclo Therapeutics, Inc.<\/strong><\/p>\n

Trappsol Cyclo, developed by Cyclo Therapeutics, Inc., is a proprietary formulation of hydroxypropyl beta cyclodextrin that has demonstrated promising results in multiple clinical studies for managing cholesterol transport. Acting as a substitute for the defective NPC1 protein, its cyclic structure helps transport accumulated cholesterol out of cellular lysosomes, allowing it to be processed and eliminated from the cells. Trappsol Cyclo is currently undergoing clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC), a rare, progressive, and fatal genetic disorder, as well as Alzheimer’s disease, a progressive neurological condition in which elevated cholesterol is also a known risk factor. The drug has received FDA Fast Track Designation for NPC treatment and has been granted Orphan Drug status by both the FDA and the European Medicines Agency. It is presently in Phase III clinical development for Niemann-Pick Type C Disease.<\/p>\n

Learn more about the novel and emerging Niemann-Pick Type C Disease pipeline therapies<\/a>. <\/strong><\/p>\n

 <\/p>\n

Niemann-Pick Type C Disease Therapeutics Assessment<\/strong><\/p>\n

By Product Type<\/strong><\/p>\n

• Mono<\/p>\n

• Combination<\/p>\n

• Mono\/Combination.<\/p>\n

 <\/p>\n

By Stage<\/strong><\/p>\n

• Late-stage products (Phase III)<\/p>\n

• Mid-stage products (Phase II)<\/p>\n

• Early-stage product (Phase I) along with the details of<\/p>\n

• Pre-clinical and Discovery stage candidates<\/p>\n

• Discontinued & Inactive candidates<\/p>\n

 <\/p>\n

By Route of Administration<\/strong><\/p>\n

• Oral<\/p>\n

• Intravenous<\/p>\n

• Subcutaneous<\/p>\n

• Parenteral<\/p>\n

• Topical<\/p>\n

 <\/p>\n

By Molecule Type<\/strong><\/p>\n

• Recombinant fusion proteins<\/p>\n

• Small molecule<\/p>\n

• Monoclonal antibody<\/p>\n

• Peptide<\/p>\n

• Polymer<\/p>\n

• Gene therapy<\/p>\n

 <\/p>\n

Scope of the Niemann-Pick Type C Disease Pipeline Report <\/strong><\/p>\n

• Coverage: Global<\/p>\n

• Key Niemann-Pick Type C Disease Companies: Zevra Therapeutics, Azafaros, Cyclo Therapeutics, IntraBio, SOM Biotech, ENDECE, and others.<\/p>\n

• Key Niemann-Pick Type C Disease Pipeline Therapies: Arimoclomol, AZ 3102, Trappsol Cyclo, IB1001, SOM-0208, NDC 1308, and others.<\/p>\n

Explore detailed insights on drugs used in the treatment of Niemann-Pick Type C Disease here<\/a>.<\/strong><\/p>\n

 <\/p>\n

Table of Contents<\/strong><\/p>\n

1. Introduction<\/p>\n

2. Executive Summary<\/p>\n

3. Niemann-Pick Type C Disease Pipeline: Overview<\/p>\n

4. Analytical Perspective In-depth Commercial Assessment<\/p>\n

5. Niemann-Pick Type C Disease Pipeline Therapeutics<\/p>\n

6. Niemann-Pick Type C Disease Pipeline: Late-Stage Products (Phase III)<\/p>\n

7. Niemann-Pick Type C Disease Pipeline: Mid-Stage Products (Phase II)<\/p>\n

8. Niemann-Pick Type C Disease Pipeline: Early Stage Products (Phase I)<\/p>\n

9. Therapeutic Assessment<\/p>\n

10. Inactive Products<\/p>\n

11. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n

12. Key Companies<\/p>\n

13. Key Products<\/p>\n

14. Unmet Needs<\/p>\n

15. Market Drivers and Barriers<\/p>\n

16. Future Perspectives and Conclusion<\/p>\n

17. Analyst Views<\/p>\n

18. Appendix<\/p>\n

 <\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Jatin Vimal
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Niemann-Pick Type C Disease Pipeline The therapeutic pipeline for Niemann-Pick Type C (NPC) disease is advancing to address the urgent need to slow its progressive neurological decline. Current treatments like miglustat delay symptoms but don\u2019t target underlying cholesterol and lipid … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,417,420],"tags":[],"class_list":["post-757184","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Marketing-Sales","category-Science"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/757184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=757184"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/757184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=757184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=757184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=757184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}